CN109394799A - Natural drug composition of the extract containing ganoderma lucidum and its preparation method and application - Google Patents
Natural drug composition of the extract containing ganoderma lucidum and its preparation method and application Download PDFInfo
- Publication number
- CN109394799A CN109394799A CN201811624807.7A CN201811624807A CN109394799A CN 109394799 A CN109394799 A CN 109394799A CN 201811624807 A CN201811624807 A CN 201811624807A CN 109394799 A CN109394799 A CN 109394799A
- Authority
- CN
- China
- Prior art keywords
- extract
- ganoderma lucidum
- drug composition
- natural drug
- hepiali chen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000284 extract Substances 0.000 title claims abstract description 71
- 240000008397 Ganoderma lucidum Species 0.000 title claims abstract description 52
- 235000001637 Ganoderma lucidum Nutrition 0.000 title claims abstract description 52
- 239000003814 drug Substances 0.000 title claims abstract description 28
- 229940079593 drug Drugs 0.000 title claims abstract description 24
- 239000000203 mixture Substances 0.000 title claims abstract description 17
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 241000143459 Hirsutella Species 0.000 claims abstract description 31
- 241000222336 Ganoderma Species 0.000 claims abstract description 8
- 238000000034 method Methods 0.000 claims abstract description 8
- 238000000605 extraction Methods 0.000 claims description 22
- 239000012141 concentrate Substances 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 5
- 238000007598 dipping method Methods 0.000 claims description 5
- 238000009413 insulation Methods 0.000 claims description 5
- 238000002791 soaking Methods 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 229940041181 antineoplastic drug Drugs 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 abstract description 4
- 239000008236 heating water Substances 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 230000008569 process Effects 0.000 abstract description 2
- 238000003809 water extraction Methods 0.000 abstract description 2
- 206010028980 Neoplasm Diseases 0.000 description 17
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 210000003462 vein Anatomy 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 4
- 238000007654 immersion Methods 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 230000001151 other effect Effects 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 238000001291 vacuum drying Methods 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 229930182558 Sterol Natural products 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 238000012109 statistical procedure Methods 0.000 description 2
- 150000003432 sterols Chemical class 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 241001646834 Mesona Species 0.000 description 1
- 208000025844 Prostatic disease Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000002416 angiotensin derivative Substances 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000037111 immune power Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000012666 negative regulation of transcription by glucose Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- -1 triterpene compounds Chemical class 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/066—Clavicipitaceae
- A61K36/068—Cordyceps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses natural drug composition of a kind of supercritical extract containing ganoderma lucidum and its preparation method and application, which includes the ganoderma lucidum extract and Hirsutella hepiali Chen et Shen filament extract that weight ratio is 2:1-1:2.Present invention process is simple, and production cost is low, utilizes supercritical CO2Extracting ganoderma combine heating water extraction method extract Hirsutella hepiali Chen et Shen filament, by the two extract according to a certain percentage made of natural drug composition, have significant anti-tumor function.
Description
Technical field
The invention belongs to field of health care food, and in particular to a kind of natural drug composition and its system of the extract containing ganoderma lucidum
Preparation Method and application.
Background technique
Ganoderma lucidum is also known as seocho, mesona, sweet natured, and China's tradition rare traditional Chinese medicine is considered as by chinese tradition medicine always
Nourishing and fit keeping function, the precious Chinese herbal medicine for consolidating righting.The ingredient of ganoderma lucidum is abundant, including ganoderma lucidum polysaccharide, triterpene and steroid ingredient, nucleosides,
Protein and microelement etc., wherein ganodenic acid and sterols and ganoderma lucidum polysaccharide are most important active materials, in recent years
Come the emphasis always studied.Modern medicine and pharmacology studies ganoderma lucidum and its extract discovery, and ganoderma lucidum triterpene compounds have anti-swollen
Tumor, liver protection reduce blood glucose, inhibit angiotensins, anti-oxidant and other effects；Ganoderma lucidum polysaccharide has antitumor, aging, improves immune
Power removes free radical, reduces blood glucose and other effects；The ability that there is ganoderma lucidum sterol enhancing human body to resist the disease, reduces in blood
Cholesterol concentration, prevention prostatic disorders and other effects.These ingredients respectively work, and have synergistic effect between ingredient again.
Existing market product is only the preparation of single Ganodenna Lucidum P.E, not by Hirsutella hepiali Chen et Shen filament extract and
Ganodenna Lucidum P.E is combined, the combination preparation for better antineoplastic action.
Summary of the invention
The technical problem to be solved by the present invention is to be directed to the status of the prior art, a kind of containing with antitumor efficacy is provided
The natural drug composition of ganoderma lucidum extract and Hirsutella hepiali Chen et Shen filament extract.
The purpose of the present invention is what is be accomplished by the following way:
A kind of natural drug composition of the extract containing ganoderma lucidum, the pharmaceutical composition include that weight ratio is 2:1-1:2's
Ganoderma lucidum extract and Hirsutella hepiali Chen et Shen filament extract.
It is preferred that ganoderma lucidum extract and Hirsutella hepiali Chen et Shen filament extract are mixed according to the ratio of 2:1-1:1.
Further preferred ganoderma lucidum extract and Hirsutella hepiali Chen et Shen filament extract are mixed according to the ratio of 2:1.
Oral preparation is made in the pharmaceutical composition and pharmaceutically acceptable auxiliary material.The oral preparation is preferably piece
Agent, capsule, granule, pill.
The preparation method of the natural drug composition of the above-mentioned extract containing ganoderma lucidum the following steps are included:
(1) ganoderma lucidum be crushed into 10~20 meshes, the ganoderma lucidum essence powder obtained after crushing with alcohol solution dipping 1~2 hour,
Ganoderma lucidum essence powder after immersion is subjected to CO2Supercritical extract, extraction conditions: 38~42 DEG C of extraction kettle temperature, extraction kettle pressure 30
~35MPa, 3~4h of extraction time obtain ganoderma lucidum extract；
(2) it takes Hirsutella hepiali Chen et Shen filament that 20~30 times of volume of water is added to boil and extracts 1-2h, heat-insulation soaking 12h or more,
It boils again and extracts 1-2h, concentrate is obtained after concentration；Concentrate is dried in vacuo to obtain Hirsutella hepiali Chen et Shen filament extract；
(3) ganoderma lucidum extract and Hirsutella hepiali Chen et Shen filament extract is taken to mix according to weight ratio 2:1-1:2.
The volume Hirsutella hepiali Chen et Shen filament that the present invention uses is purchased from Hangzhou Zhong Zhikang mushroom Bioisystech Co., Ltd.
Above-mentioned natural drug composition has remarkable result in the application prepared in anti-tumor drug.
Beneficial effects of the present invention compared with the prior art: present invention process is simple, and production cost is low, and utilization is overcritical
CO2Extracting ganoderma extracts Hirsutella hepiali Chen et Shen filament in conjunction with heating water extraction method, according to a certain percentage by the two extract
Manufactured natural drug composition has significant anti-tumor function.
Below by way of the drug effect of the inhibiting effect to animal transplanting tumor, invention is further explained:
1 test material
1.1 test medicines: the present invention (1 product of embodiment, referred to as No. 1), (2 product of embodiment, referred to as No. 2), (embodiment
3 products, referred to as No. 3), ganoderma lucidum extract group (whole ganoderma lucidum extracts, referred to as No. 4), Hirsutella hepiali Chen et Shen filament group are (all
Hirsutella hepiali Chen et Shen filament extract, referred to as No. 5).
1.2 animals: ICR kind small white mouse, 18-22g, half male and half female are provided, feed by China Medicine University's Animal Lab.
For pellet, rearing conditions: air-conditioned room, 18-24 DEG C of temperature, relative humidity 70%.
1.3 positive drugs: cyclophosphamide (CTX), Jiangsu Sheng Di Pharmaceuticals Ltd.Specification: 0.2g/ bottles.
The main contents of 2 experiments
2.1 No. 1, No. 2, No. 3, No. 4, No. 5 tail vein injections are to the inhibiting effect of mice-transplanted tumor Heps.
2.2 No. 1, No. 2, No. 3, No. 4, No. 5 tail vein injections are to the inhibiting effect of mice-transplanted tumor S180.
3 experimental methods and step
3.1 No. 1, No. 2, No. 3, No. 4, No. 5 tail vein injections are to the inhibiting effect of mice-transplanted tumor Heps.
3.1.1 administration route: No. 1, No. 2, No. 3, No. 4, No. 5 tail vein injections (iv)
3.1.2 dosage period: it is inoculated with Heps solid type by transplanted tumor organon, inoculation is administered after 24 hours, and iv gives
Medicine is administered 4 times altogether once every other day, and mouse is dissected in execution in the 2nd day after drug withdrawal.
3.1.3 dosage is arranged 7 groups, is respectively as follows:
Blank control group (physiological saline)
No. 1: 3mg/kg
No. 2: 3mg/kg
No. 3: 3mg/kg
No. 4: 3mg/kg
No. 5: 3mg/kg
CTX:30mg/kg
3.1.4 administered volume: 0.4ml/20g
3.1.5 it experimental method: takes above-mentioned specification mouse 70 to be only inoculated with Heps solid type by transplanted tumor research method, connects
24 hours title mouse weights after kind, and 7 groups are randomly divided into, every group 10, half male and half female, blank control group and CTX group are respectively yin, yang
Property control group.Inoculation is administered after 24 hours, and iv administration is administered 4 times altogether once every other day, mouse weighing in the 2nd day, place after drug withdrawal
Dead tumor-bearing mice simultaneously separates tumor mass, claims knurl weight, and the data obtained carries out statistical procedures (t inspection).
3.1.6 experimental result
It the results are shown in Table 1, the results showed that, compared with blank control group, No. 1, No. 2 group iv administrations inhibit Heps's with can dramatically
Tumour growth acts on (P < 0.05, P < 0.01), while having an attenuating effect to the weight of experiment mice, but with positive drug CTX group
It compares, influences very little, and effect is better than No. 3, No. 4 and No. 5.
Table 11, No. 2, No. 3 No. .4, inhibiting effect (X ± SD) (n=10) of No. 5 iv to mice-transplanted tumor Heps
Note: compared with blank control group, * P < 0.05**P < 0.01
No. 3.21, No. 2, No. 3, No. 4, inhibiting effect of No. 5 tail vein injections to mice-transplanted tumor S180
3.2.1 administration route: No. 1, No. 2, No. 3, No. 4, No. 5 tail vein injections (iv)
3.2.2 dosage period: it is inoculated with S180 solid type by transplanted tumor organon, inoculation is administered after 24 hours, and iv gives
Medicine is administered 4 times altogether once every other day, and mouse is dissected in execution in the 2nd day after drug withdrawal.
3.2.3 dosage is arranged: setting 7 groups altogether, is respectively as follows:
Blank control group (physiological saline)
No. 1: 3mg/kg
No. 2: 3mg/kg
No. 3: 3mg/kg
No. 4: 3mg/kg
No. 5: 3mg/kg
CTX:30mg/kg
3.2.4 administered volume: 0.4ml/20g
3.2.5 it experimental method: takes above-mentioned specification mouse 70 to be only inoculated with S180 solid type by transplanted tumor research method, connects
24 hours title mouse weights after kind, and 7 groups are randomly divided into, every group 10, half male and half female, blank control group and CTX group are respectively yin, yang
Property control group.Inoculation is administered after 24 hours, and iv administration is administered 4 times altogether once every other day, mouse weighing in the 2nd day, place after drug withdrawal
Dead tumor-bearing mice simultaneously separates tumor mass, claims knurl weight, and the data obtained carries out statistical procedures (t inspection).
3.2.6 4 be the results are shown in Table, the results showed that, compared with blank control group, No. 1 group iv administration inhibits in which can dramatically
The tumour growth of S180 acts on (P < 0.01), while having an attenuating effect to the weight of experiment mice, but with positive drug CTX group phase
Than influencing very little, and effect is substantially better than No. 2-5.
Table 41, No. 2, inhibiting effect (X ± SD) (n=10) of No. 3 iv to mice-transplanted tumor S180
Note: compared with blank control group, * P < 0.05**P < 0.01
Therefore, the present invention uses ganoderma lucidum extract together with Hirsutella hepiali Chen et Shen filament extract combination, ganoderma lucidum
It is mutually coordinated between extract and Hirsutella hepiali Chen et Shen filament extract, interaction, in conjunction with the two advantage, significant raising group
Object utilization rate is closed, enhancing inhibits the effect of animal transplanting tumor.
Specific embodiment
Explanation is further expalined to the present invention below by way of specific embodiment:
Embodiment 1
(1) ganoderma lucidum be crushed into 10~20 meshes, the glossy ganoderma powder obtained after crushing with 95% alcohol solution dipping 1 hour,
Glossy ganoderma powder after immersion is subjected to CO2Supercritical extract, extraction conditions: 40 DEG C of extraction kettle temperature, extraction time 3h, extracting pressure
30MPa obtains ganoderma lucidum extract；
(2) it after taking Hirsutella hepiali Chen et Shen filament that 30 times of volume of water is added to boil extraction 2h, then heat-insulation soaking 12h, boils again
2h is extracted in boiling, and concentrate is obtained after concentration；Concentrate vacuum drying, obtains Hirsutella hepiali Chen et Shen filament extract；
(3) ganoderma lucidum extract and Hirsutella hepiali Chen et Shen filament extract is taken to mix according to weight ratio 2:1.
Embodiment 2
(1) ganoderma lucidum be crushed into 10~20 meshes, the glossy ganoderma powder obtained after crushing with 95% alcohol solution dipping 2 hours,
Ganoderma lucidum essence powder after immersion is subjected to CO2Supercritical extract, extraction conditions: 38 DEG C of extraction kettle temperature, extraction kettle pressure 32MPa,
Extraction time 4h obtains ganoderma lucidum extract；
(2) it after taking Hirsutella hepiali Chen et Shen filament that 20 times of volume of water is added to boil extraction 1h, then heat-insulation soaking 12h, boils again
2h is extracted in boiling, and concentrate is obtained after concentration；Concentrate vacuum drying, obtains Hirsutella hepiali Chen et Shen filament extract；
(3) ganoderma lucidum extract and Hirsutella hepiali Chen et Shen filament extract is taken to mix according to weight ratio 1:1.
Embodiment 3
(1) ganoderma lucidum be crushed into 10~20 meshes, the glossy ganoderma powder obtained after crushing with 95% alcohol solution dipping 2 hours,
Glossy ganoderma powder after immersion is subjected to CO2Supercritical extract, extraction conditions: 42 DEG C of extraction kettle temperature, extraction kettle pressure 35MPa, extraction
Time 4h is taken, ganoderma lucidum extract is obtained；
(2) it after taking Hirsutella hepiali Chen et Shen filament that 25 times of volume of water is added to boil extraction 2h, then heat-insulation soaking 12h, boils again
2h is extracted in boiling, and concentrate is obtained after concentration；Concentrate vacuum drying, obtains Hirsutella hepiali Chen et Shen filament extract；
(3) ganoderma lucidum extract and Hirsutella hepiali Chen et Shen filament extract is taken to mix according to weight ratio 1:2.
Claims (7)
1. the natural drug composition of the extract containing ganoderma lucidum, it is characterised in that the pharmaceutical composition includes that weight ratio is 2:1-1:
2 ganoderma lucidum extract and Hirsutella hepiali Chen et Shen filament extract.
2. the natural drug composition of the extract according to claim 1 containing ganoderma lucidum, it is characterised in that ganoderma lucidum extract and
Hirsutella hepiali Chen et Shen filament extract is mixed according to the ratio of 2:1-1:1.
3. the natural drug composition of the extract according to claim 1 containing ganoderma lucidum, it is characterised in that ganoderma lucidum extract and
Hirsutella hepiali Chen et Shen filament extract is mixed according to the ratio of 2:1.
4. the natural drug composition of the extract according to claim 1 containing ganoderma lucidum, it is characterised in that the medicine group
It closes object and oral preparation is made in pharmaceutically acceptable auxiliary material.
5. the natural drug composition of the extract according to claim 1 containing ganoderma lucidum, it is characterised in that the oral system
Agent is tablet, capsule, granule, pill.
6. a kind of preparation method of the natural drug composition of the extract described in claim 1 containing ganoderma lucidum, it is characterised in that should
Method the following steps are included:
(1) ganoderma lucidum be crushed into 10~20 meshes, the glossy ganoderma powder obtained after crushing will be impregnated with alcohol solution dipping 1~2 hour
Ganoderma lucidum essence powder afterwards carries out CO2Supercritical extract, extraction conditions: 38~42 DEG C of extraction kettle temperature, extraction kettle pressure 30~
35MPa, 3~4h of extraction time obtain ganoderma lucidum extract；
(2) it takes Hirsutella hepiali Chen et Shen filament that 20~30 times of volume of water is added to boil and extracts 1-2h, heat-insulation soaking 12h or more, again
It boils and extracts 1-2h, concentrate is obtained after concentration；Concentrate is dried in vacuo to obtain Hirsutella hepiali Chen et Shen filament extract；
(3) ganoderma lucidum extract and Hirsutella hepiali Chen et Shen filament extract is taken to mix according to weight ratio 2:1-1:2.
7. the natural drug composition of the extract containing ganoderma lucidum described in claim 1-5 is preparing answering in anti-tumor drug
With.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811624807.7A CN109394799B (en) | 2018-12-28 | 2018-12-28 | Natural pharmaceutical composition containing ganoderma lucidum extract and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811624807.7A CN109394799B (en) | 2018-12-28 | 2018-12-28 | Natural pharmaceutical composition containing ganoderma lucidum extract and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109394799A true CN109394799A (en) | 2019-03-01 |
| CN109394799B CN109394799B (en) | 2021-05-28 |
Family
ID=65462353
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811624807.7A Active CN109394799B (en) | 2018-12-28 | 2018-12-28 | Natural pharmaceutical composition containing ganoderma lucidum extract and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109394799B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110237107A (en) * | 2019-05-31 | 2019-09-17 | 嘉兴市爵拓科技有限公司 | Preparation method, its composition and its application of a kind of mountain Soviet Union extract |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102379905B (en) * | 2011-06-22 | 2013-07-24 | 南京中科药业有限公司 | Ganoderma lucidum spore oil-containing Chinese medicinal composition with efficient cancer resistance |
| CN108392500A (en) * | 2018-03-30 | 2018-08-14 | 上海市农业科学院 | A method of preparing ganodenic acid |
-
2018
- 2018-12-28 CN CN201811624807.7A patent/CN109394799B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102379905B (en) * | 2011-06-22 | 2013-07-24 | 南京中科药业有限公司 | Ganoderma lucidum spore oil-containing Chinese medicinal composition with efficient cancer resistance |
| CN108392500A (en) * | 2018-03-30 | 2018-08-14 | 上海市农业科学院 | A method of preparing ganodenic acid |
Non-Patent Citations (1)
| Title |
|---|
| 陈志蓉等: "蝙蝠蛾被毛孢菌丝体通过激活TLR2、TLR4和Dectin-1诱导Th1型免疫反应 ", 《中国免疫学杂志》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110237107A (en) * | 2019-05-31 | 2019-09-17 | 嘉兴市爵拓科技有限公司 | Preparation method, its composition and its application of a kind of mountain Soviet Union extract |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109394799B (en) | 2021-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1762236B (en) | Health-caring product capable of increasing human immunity and its preparation method | |
| JP5946457B2 (en) | Application of herbal medicine composition to the preparation of health foods and medicines for the relief and prevention treatment of physical fatigue | |
| CN101152007B (en) | Health-care products composition and method for preparing the same | |
| CN107114783A (en) | It is a kind of to strengthen the high selemium nutrition replenishers that immune and adjuvant therapy recovers | |
| CN101703530A (en) | Mixed fungus ultrafine powder and preparation method thereof | |
| CN105395919A (en) | Composition containing black fungus extract and having effect of reducing blood fat and preparation method of composition | |
| CN105727205A (en) | Composition with weight losing and blood fat reducing functions and preparing method and application thereof | |
| CN104666373A (en) | Novel use of Eurycoma longifolia Jack | |
| CN101467673A (en) | Compound ginseng health product and preparation method thereof | |
| CN104187681A (en) | Hypoglycemic and hypolipidemic health food and preparation method thereof | |
| CN105495620A (en) | Plant extract composition with functions of enhancing immunity and reducing blood fat | |
| CN109394799A (en) | Natural drug composition of the extract containing ganoderma lucidum and its preparation method and application | |
| CN102846879B (en) | Composition for depressing blood fat | |
| CN106581166A (en) | Anti-fatigue food, health product or pharmaceutical composition | |
| CN104082747A (en) | Health food with function of improving body immunity and preparation method of health food | |
| CN104745424A (en) | Maca health wine and preparation method thereof | |
| CN107375509A (en) | It is a kind of to be used to improve immunity, the health food of pre- anti-cancer | |
| CN103330721A (en) | Sea cucumber flower extract for treating premature ovarian failure and preparation method thereof | |
| CN1115159C (en) | Red sage containing medicine composition and its preparation and use | |
| CN105125738A (en) | Traditional Chinese medicinal composition as well as preparation method and application thereof | |
| CN106039032A (en) | Cordyceps sinensis composition, compound preparation, preparation method of compound preparation and application of cordyceps sinensis composition | |
| CN109674942A (en) | A kind of Antilipidemic pharmaceutical compositions, preparation method and applications | |
| CN107648281A (en) | Cordyceps sinensis composition capable of reducing blood fat | |
| CN104510857B (en) | A kind of Chinese medicinal effective-part composition for blood fat reducing and preparation thereof | |
| CN109125623A (en) | It is a kind of for treating the pharmaceutical composition of hepatopathy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |